Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd.

9.60
USD
+2.60
(+37.14%)
0.87EPS
Jan 29Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
451.07
448.4
370.84
417.67
398.74
376.12
349.76
362.96
426.32
602.7
635.36
778.55
781.27
848.54
Basic EPS, GAAP
-20.12
-34.84
66.53
-22.18
-85.41
46.85
61.26
87.96
171.21
145.57
132.86
118.29
109.69
137
Free Cash Flow per Basic Share
-89.7
-91.13
-129.43
-45.19
7.83
43.06
42.95
87.16
104.21
-22.86
-156.1
-93.61
71.84
- -
Dividend per Share
0.03
- -
- -
- -
- -
- -
2.97
4.95
19.85
59.68
49.78
50.44
50.05
- -
Book Value per Share
262.29
241.77
413.49
539.28
628.33
682.38
391.24
377.94
469.86
629.61
819.43
961.35
1,035.76
947.85
Tangible Book Value per Share
257.11
236.87
404.9
530.36
621.39
680.16
386.57
372.81
464.76
588.79
767.56
910.83
984.78
898.1
Basic Weighted Avg Shares
38
40
40
41
42
42
42
42
42
42
42
42
42
42
Sales/Revenue/Turnover
16,926
17,835
14,750
17,244
16,601
15,659
14,561
15,111
17,748
25,091
26,450
32,414
32,525
35,326
Operating Margin (%)
-4.28
-3.57
-26.19
-10.39
-4.2
5.3
15.3
16.74
23.64
20.9
15.74
9.21
8.16
11.78
Depreciation Expense
1,318
1,392
1,592
1,546
1,473
1,362
1,229
1,188
1,177
1,600
1,868
2,611
3,432
- -
Net Income, GAAP
-755
-1,386
2,646
-916
-3,556
1,950
2,550
3,662
7,128
6,060
5,531
4,925
4,567
5,704
Effective Tax Rate (%)
897.97
- -
25.45
- -
- -
- -
13.54
11.92
12.42
22.02
20.89
19.1
27.42
28.36
Profit Margin (%)
-4.46
-7.77
17.94
-5.31
-21.42
12.46
17.52
24.23
40.16
24.15
20.91
15.19
14.04
16.15
Working Capital
2,819
-315
-3,190
-1,530
-4,865
-6,101
-541
2,864
2,761
2,888
7,270
3,684
3,663
9,754
LT Debt
13,394
11,517
12,005
11,298
7,409
4,603
8,925
9,199
6,196
9,837
18,361
22,696
21,589
30,239
Total Equity
10,515
9,644
16,475
22,473
26,216
28,478
16,382
15,839
19,723
26,359
34,161
40,086
43,489
39,818
Return on Invested Capital (%)
19.53
- -
-7.9
- -
- -
- -
5.05
7.3
12.5
10.86
6.11
3.48
2.37
3.6
Return on Capital (%)
-11.09
- -
8.13
- -
- -
- -
7.01
12.73
25.09
16.67
10.72
7.63
6.04
7.29
Return on Common Equity (%)
-11.48
-13.82
20.31
-4.71
-14.63
7.15
11.41
22.87
40.39
26.48
18.34
13.29
10.99
14.75

Capital Structure

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
19,670
19,570
18,571
LT Borrowings
21,121
17,286
29,477
LT Finance Leases
468
727
761
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
61,107
46,726
- -

Working Capital

JPY

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
42,989
40,146
48,941
Cash, Cash Equivalents & STI
18,536
14,334
24,400
Accounts Receivable, Net
7,305
7,174
6,945
Inventories
15,114
17,207
16,101
Total Current Liabilities
39,325
39,494
39,187
Payables & Accruals
- -
- -
- -
ST Debt
19,670
19,570
18,571
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.95%
22.72%
8.49%
Free Cash Flow
63.51%
52.74%
-176.74%
Net Income, GAAP
12.58%
10.54%
-7.27%
Sales/Revenue/Turnover
9.14%
17.43%
0.34%
Total Cash Common Dividend
- -
97.06%
-0.78%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,550
6,959
9,727
10,178
32,414
2026
6,478
8,289
6,429
11,329
32,525
2027
7,869
9,699
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.94
29.04
45.03
41.3
118.29
2026
6.26
19.23
29.06
55.15
109.69
2027
25.56
27.24
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
50.44
2026
- -
- -
- -
- -
50.05
2027
- -
- -
- -
- -
- -

Company Description

CEO
Ryoichi Nagata
Full Time Employees
1,522
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
2438 Miyanoura-cho Tokyo Japan 891-1394
IPO Date
Mar 8, 2004
Website
snbl.co.jp
Business
Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japan-based contract research organization (CRO) providing comprehensive pharmaceutical development services, including non-clinical studies such as single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, toxicokinetic studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies; clinical services encompassing investigator brochure preparation support, clinical trial protocol creation support, investigational drug allocation, monitoring, quality management, data management, statistical analysis, comprehensive report creation support, electronic application support, regulatory affairs consulting, site management organization services, and clinical CRO services from Phase I to Phase IV; translational research focused on research and development of vaccines, therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines; as well as medipolis operations including geothermal power generation, hotel accommodations, wellbeing services, cleaning, clerical work, and welfare services. The company serves pharmaceutical companies, biotech ventures, universities, and research institutions primarily in Japan and internationally, with operations spanning the United States, China, Indonesia, Cambodia, and Europe for non-human primate breeding and testing facilities. Founded in September 1957 and headquartered in Kagoshima City, Japan, with additional key offices in Tokyo and facilities worldwide, SNBL maintains subsidiaries like SNBL U.S.A., Ltd., Inari Research Co., Ltd., Satsuma Pharmaceuticals (made a consolidated subsidiary in 2023 following its 2023 acquisition), and the joint venture SNBL PPD with Thermo Fisher Scientific. Recent developments include the establishment of a new research building at the Kagoshima headquarters in 2024 equipped for Microphysiological Systems (MPS); a business alliance and joint fund with SBI Holdings, Inc. announced in July 2024 and formalized in September 2024 to support early-stage startups in North America through investments in SNBL's U.S. incubation facility in Washington State; a joint research and development agreement with Cardio Intelligence Inc. for AI-based long-duration electrocardiogram analysis; and the affiliate Shin Nippon Science Tasso's certification of the TS Blood Collection Kit as a regulated medical device under Japan's Pharmaceutical and Medical Device Act.